Director Keith Manchester Sells $32.6 Million in Roivant Shares Amidst Broader Insider Distribution
ROIV has more than doubled off its 52-week low of $8.73.
Summary
Roivant Sciences Director Keith S. Manchester disposed of over $32.6 million worth of common shares, contributing to a significant pattern of insider selling at the company.
Key Events · Ownership and Investor Activity · ROIV
-
Director Sells Significant Stake
Keith S. Manchester, a Director of Roivant Sciences, sold 1,225,784 common shares through five open market transactions.
-
Substantial Transaction Value
The total value of the shares sold amounted to $32,658,518, executed at prices ranging from $26.49 to $26.76 per share.
-
Sales Near 52-Week Highs
The sales occurred between February 11-13, 2026, while the company's stock is trading near its 52-week high, potentially indicating insiders are locking in gains.
-
Part of Broader Insider Distribution
This sale contributes to a pattern of over $74 million in net insider sales at Roivant Sciences over the past 90 days, indicating a wider trend of key personnel reducing their holdings.
Analysis · ROIV · Life Sciences
This substantial sale by Director Keith S. Manchester, totaling $32.6 million, represents a notable disposition of shares, particularly as it occurs while the stock is trading near its 52-week high. The transaction is part of a broader trend of insider selling at Roivant Sciences, with over $74 million in net sales by three active insiders in the last 90 days, including another significant sale by Director Daniel Allen Gold reported on the same day. This pattern of distribution by key personnel could signal a lack of conviction in the company's near-term prospects or a desire to lock in gains at elevated share prices. Investors should monitor future insider activity for further indications of sentiment.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.8% of the 1864 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ROIV was trading at $26.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.9B. The 52-week trading range was $8.73 to $27.94. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.